#Paris #France #GLP-1 #Havas Health Network #Shape Shifting

Havas Health Network Launches GLP-1 Consultancy in Paris

In a significant move for health innovation, Havas Health Network is officially launching its GLP-1 consultancy in Europe. The flagship event, titled "Shape Shifting: Spotlight on GLP-1", is set to take place on March 13 at the Havas Village in Paris. This gathering will feature key opinion leaders, brand strategy experts, and health professionals, focusing on the transformative effects of GLP-1 treatments on the health and wellness landscape.

Exploring GLP-1's Impact

GLP-1, which stands for glucagon-like peptide-1, is rapidly emerging as a game-changer within the health sector, reshaping consumer behaviors and market trends. Originally developed for diabetes management, these medications are now recognized for their broader applications, impacting lifestyle choices beyond weight loss. Havas Health Network's consultancy aims to provide invaluable insights to brands and marketing specialists on navigating this evolution in health care.

Inspired by the successful GLP101 event held in New York last November, "Shape Shifting" is geared towards equipping European brand managers with essential knowledge to harness the GLP-1 revolution. Chloé Depiesse, the General Manager of Havas Health Network, remarked on the cultural nuances that differentiate the North American market from the European one, emphasizing the need to adapt messaging and strategies accordingly.

A Promising Market

Forecasts indicate that the global market for GLP-1 will soar to approximately $5.56 billion by 2030. The increase can be attributed to the ongoing launch of new GLP-1 medications and a rising prevalence of diabetes in high-income nations. This surge calls for tailored approaches as consumers begin to engage with these treatments beyond traditional health care settings, ultimately affecting their lifestyle choices.

Commitment to Innovation

Anna Maria Marra, the CEO for Europe at Havas Health Network, highlighted the company's dedication to providing innovative solutions that address the evolving demands of the GLP-1 market. Both leaders reiterate the importance of educating clients and partners about the uses and advantages of GLP-1 treatments in the European context.

As Havas Health Network embarks on this exciting consultancy initiative, stakeholders are encouraged to engage and explore how they can adapt to the rapidly changing environment influenced by GLP-1 treatments. The "Shape Shifting" event marks a pivotal moment for Havas, as it commits to fostering discussions on the scientific basis and market implications of GLP-1 treatments.

Conclusion

This landmark event is not only a presentation of Havas Health Network's vision for the future of health and wellness but also an opportunity for brand leaders to gain vital insights. With GLP-1 poised to lead a transformation in health treatments and consumer habits across Europe, "Shape Shifting" promises to be a critical platform for evolving brand strategies and fostering innovative health solutions.

For more information about Havas Health Network's GLP-1 consultancy and how your brand can benefit, visit Havas Health.

• ---